Prompt treatment following traumatic brain injury (TBI) lowers risk of developing Alzheimer’s disease (AD) in subsequent years by up to 41%. The corresponding study was published in the Journal of ...

A recent study led by Mass General Brigham researchers found that a nasal spray developed to target inflammation in the brain could be used to treat chronic symptoms of traumatic brain injury. A nasal ...

TBI triggers both primary mechanical damage and delayed secondary injuries like inflammation and neurodegeneration. Cognitive effects may include memory loss, mood swings, and impaired social judgment ...

Getting treatment within one week of a serious head injury can reduce the risk of developing Alzheimer’s disease by up to 41%, according to new research from Case Western Reserve University. The ...

Traumatic Brain Injury (TBI) is a leading cause of morbidity and mortality worldwide, affecting approximately 69 million individuals annually according to the Global Burden of Disease Study (2019).

Our Brain Injury Program specialists are here to help you get back to your everyday activities after your brain injury. It's our goal to help regain your independence and adapt to your new lifestyle.

Advanced tools offer improved insights into patients’ condition and their potential for recovery. What’s New: After more than half a century, assessment of traumatic brain injuries gets an overhaul.

Please provide your email address to receive an email when new articles are posted on . The framework centers on clinical, imaging, biomarker and external influences on TBI. The framework can be ...

Researchers find that communication between key brain regions shortly after injury may predict long-term functional recovery ...

Electrocardiographic changes, arrhythmias, and increased cardiac enzymes have been reported in patients with TBI, but no data are published on 24-hr Holter monitoring in severe pediatric head trauma ...

The EndRAD study showed non-TBI conditioning in B-ALL patients achieved comparable EFS and OS rates to TBI-based regimens. The trial's primary endpoint was met with a two-year EFS rate of 76.3% and an ...